Methods and bioavailability highly permeable compounds for treatment of viral diseases
By combining the treatment of avermectin and the host substance to form a high bioavailability and highly permeable solid dispersion, the problem of insufficient concentration of compounds in vivo is solved and a more effective viral inhibition effect is achieved.
CN120091810APending Publication Date: 2025-06-03基里尔·迪丹克
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202380043387.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-15
- Filing Date
- 2023-03-27
- Publication Date
- 2025-06-03
AI Technical Summary
Technical Problem
Existing compounds show antiviral activity in vitro, but are difficult to achieve effective concentrations in vivo, resulting in insufficient therapeutic effect and insufficient bioavailability and permeability.
Method used
The FORMULA I compound is formed by combining the treatment of avermectin or its derivatives with the host substance by using a method of a high bioavailability and highly permeable solid dispersion or an aqueous solution or suspension thereof, and the high bioavailability and highly permeable non-covalent complex FORMULA II is obtained by adding a solvent thereto.
Benefits of technology
It improves the bioavailability and permeability of compounds in the body, enhances the inhibitory effect on the virus, and provides a more effective treatment plan.
✦ Generated by Eureka AI based on patent content.
Abstract
Methods and compounds are provided for treating viral infections by administering a high bioavailability, high permeability compound based on abamectin. The compounds, compositions, and methods provided are particularly useful for the treatment of severe acute respiratory syndrome coronavirus type 2, dengue virus, Chikungunya virus, yellow fever virus, Zika virus, and other viral infections.
Need to check novelty before this filing date? Find Prior Art